TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06176131

Intervention type: OTHER
Intervention: Telemedicine-based cross-sector collaboration for patient management
Description: Telemedicine support from the hospital-based cardiology heart-failure team is provided on demand defined by the needs from Primary Care and from the patient rather than plain guideline-based targets
Study: NCT05075135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swibrace 3D-splint
Description: The Swibrace 3D splint is a custom-made splint. For scanning of the forearms, the investigators will use the scanner HandySCAN300 and the therewith delivered software VXElements, the latter being necessary to create an accurate scan on the computer.~Printing of the splint will be done by Materialise, Belgium.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plaster cast
Description: The conservative gold standard treatment of distal radius and scaphoid fractures is applying a plaster cast. Therefore, patients in the control group follow standard therapy procedures.
Study: NCT05022953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education, dijital storytelling
Description: Digital story
Study: NCT05374239

Intervention type: OTHER
Group type: OTHER
Intervention: Multi-component implementation intervention
Description: The multiple-component implementation intervention will comprise of 3 key components: (1) education, (2) operational process, and (3) audit and feedback
Study: NCT06290557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY_133
Description: A recombinant chimeric bacteriophage endolysin HY-133
Study: NCT05374239

Intervention type: OTHER
Group type: OTHER
Intervention: Multi-component implementation intervention
Description: The multiple-component implementation intervention will comprise of 3 key components: (1) education, (2) operational process, and (3) audit and feedback

Intervention type: OTHER
Group type: OTHER
Intervention: Multi-component implementation intervention
Description: The multiple-component implementation intervention will comprise of 3 key components: (1) education, (2) operational process, and (3) audit and feedback

Intervention type: OTHER
Group type: OTHER
Intervention: Multi-component implementation intervention
Description: The multiple-component implementation intervention will comprise of 3 key components: (1) education, (2) operational process, and (3) audit and feedback
Study: NCT06290557

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05464979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]
Description: Esketamine at 0.5-1.0 mg/kg BW and rocuronium bromide at 0.6 mg/kg BW was given intravenously for induction intubation. After the intubation was completed, esketamine was continuously pumped at 0.3-1.5 mg/kg/h to maintain sedation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: midazolam, fentanyl
Description: Midazolam at 0.1mg/kg BW, fentanyl at 1ug/kg BW, rocuronium bromide at 0.6mg/kg BW was given intravenously for induction intubation; After the intubation was completed, sufentanil at 0.1 μg/kg/h was administered for analgesia, and remazolam tosylate at an initial dose of 0.075 mg/kg/h was administered for sedation, and the dose of remazolam tosylate was adjusted according to the RASS score.
Study: NCT05802628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium Chloride Buccal Tablets
Description: Subjects administrated single dose of Cetylpyridinium Chloride Buccal Tablet
Study: NCT06531278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome
Description: * Patients are planned to receive irinotecan liposomal (60 mg/m2; d1) of every cycle.~* 27 days a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: * Patients are planned to receive Adebrelimab (20 mg/kg; d1) of every cycle.~* 27 days a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: * Patients are planned to receive Oxaliplatin (85 mg/m2; d1) of every cycle.~* 27 days a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: * Patients are planned to receive fluorouracil (2400mg/m2; d1) of every cycle.~* 27 days a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folinate
Description: * Patients are planned to receive Calcium folinate (400mg/m2; d1) of every cycle.~* 27 days a cycle
Study: NCT05092893

Intervention type: OTHER
Intervention: Online parental questionnaires
Description: The SRS-2 is a parental 65-item questionnaire to detect difficulties in social responsiveness in children with autism spectrum disorder. Four different forms are available: preschoolers (2.5-4.5 years), school-aged children (4-18 years), adults (≥ 19 years) and adults self-report. In this study, only the form for school-aged children will be used.~The DCDQ'07 is a parental 15-item questionnaire to detect the risk of DCD in children between 5 and 15 years of age. Parents are asked to compare their child's motor performance to his/her peers using a 5-point Likert scale. The total sum score is compared to age-specific cut-off scores to determine the risk of DCD. Belgian norms are available since 2007.
Study: NCT04761926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiometry
Description: Audiometry: Thresholds from the audiogram obtained when Ponto 4 were fitted. Pure tone air conduction (AC) and bone conduction (BC) audiometry conducted at the visit.~Speech recognition in quiet: Speech intelligibility is measured in a soundproof room using the Matrix sentences presented from a loudspeaker. The Matrix test includes five-word sentences with a fixed syntactical structure and limited contextual cues. A list of 20 sentences is compiled from these words, ensuring that no sentence is repeated twice. This test will be obtained both unaided and aided (with and without the Ponto 4(s)).~Sound field Audiometry: Detection of sound field thresholds presented from a loudspeaker. Thresholds will be obtained both unaided and aided and the test order will be balanced between subjects. During these measurements, the Ponto 4 will be programmed in omni-directional mode, with noise reduction and feedback management system turned off.
Study: NCT04796831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib dihydrochloride
Description: Single oral dose of 60 mg quizartinib (2 x 30 mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-Quizartinib solution for infusion
Description: 50 μg solution for infusion containing NMT 22.84 kBq 14C in 5 mL; administered once as a 15-minute infusion
Study: NCT05416346

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Cognitive Behavioral Therapy
Description: Cognitive behavioral therapy for insomnia (CBT-i) has been showed to be effective in reducing insomnia symptoms and insomnia-related symptoms, including sleepiness, dysfunctional beliefs and attitudes about sleep, anxiety and depressive symptoms

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioral Therapy
Description: Cognitive behavioral therapy for insomnia (CBT-i) has been showed to be effective in reducing insomnia symptoms and insomnia-related symptoms, including sleepiness, dysfunctional beliefs and attitudes about sleep, anxiety and depressive symptoms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Education (SHE)
Description: The SHE group received sleep hygiene education delivered in text form, and the same intervention as the dCBT-i group did after four weeks.
Study: NCT06522828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: SSGJ-707 is a bispecific antibody against human PD-1 and VEGF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: SSGJ-707 is a bispecific antibody against human PD-1 and VEGF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: SSGJ-707 is a bispecific antibody against human PD-1 and VEGF
Study: NCT06390683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rewilding
Description: Yards of the assisted living centers will be modified with berry bushes, fruit trees, perennial yard plants, meadow flowers, cultivation boxes, organic mulch materials, decaying deadwood, leaf compost and organic plant growing media with high microbial diversity.
Study: NCT04643626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: artificial intelligence dietary android mobile application
Description: subjects use artificial intelligence dietary mobile application to monitor dietary intake
Study: NCT05881629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal position change to side-lying lateral with peanut ball
Description: Participants will be assisted into a position lying on their side, specifically the same side as the fetal spine diagnosed by ultrasound. An inflated peanut ball will be positioned between the legs to open the pelvis. They will be asked to maintain the position for 60 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Free maternal position
Description: Participants will be asked to adopt any position of their choosing and to maintain it for 60 minutes. They will be asked to not use a peanut ball during the 60 minute study period.
Study: NCT06522828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: SSGJ-707 is a bispecific antibody against human PD-1 and VEGF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: chemotherapy
Study: NCT05271916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib+Anlotinib
Description: The dose of each drug in the combination Decomitinib and Anlotinib will be escalated or de-escalated until the recommended phase II dose (RP2D) is reached. Patients will then be treated with RP2D orally once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacomitinib
Description: Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg once a day until progressive disease.
Study: NCT06522828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: chemotherapy
Study: NCT05071846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVX-ONCO-2
Description: One administration of MVX-ONCO-2 (or vaccination) consists of the implantation of 2 capsules containing MVX-2 cells and 1 injection of 4 × 10\^6 lethally irradiated autologous tumor cells. Tumor cells will have prealably been harvested from the participant through a surgical procedure.~A full treatment course with MVX-ONCO-2 consists of a total of 6 vaccinations: 4 vaccinations 1 week apart, followed by 2 boosters 2 weeks apart. Capsules are removed 1 week after implantation.
Study: NCT05810532

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4 hours of fasting time
Description: Oral intake is not allowed for 4 hours before sedation including water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 hour of fasting time
Description: Oral intake is not allowed for 4 hours before sedation, while water is allowed to intake before 1 hour of sedation
Study: NCT05229718

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Collaborative Care Model for Young Adults
Description: We designed a diabetes collaborative care model for young adults that incorporates a mental health provider alongside a diabetes care provider during joint office visits to facilitate screening and treatment of psychosocial determinants of diabetes management. The Massachusetts General Hospital (MGH) Diabetes Center will be piloting this model with a multi-disciplinary team of diabetologists, nurse practitioners, diabetes nurse educators, and mental health provider. Patients scheduled to be seen in the diabetes collaborative care model will continue to follow in the diabetes collaborative care model, with follow up visits every 3-4 months. All patients will receive routine diabetes care with lab testing, medical interventions, therapies and referrals performed at the discretion of the patients' providers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Model
Description: Patients enrolled in this arm will receive routine diabetes care per usual care at the Massachusetts General Hospital (MGH) Diabetes Center, with lab testing, medical interventions, therapies and referrals performed at the discretion of the patients' providers. In the usual care model, behavioral/mental health and social work services are available on a referral basis and are not integrated into a patients' routine appointment. Screening and treatment of psychosocial determinants of diabetes management are at done at the discretion of the patients' provider. Frequency of follow up visits is at the discretion of the patients' provider.
Study: NCT04744935

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1064 nm long-pulse Nd:YAG laser
Description: BCC lesion will be treated with long-pulse 1064 laser, with surface temperature monitored by infrared camera.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1064 nm long-pulse Nd:YAG laser
Description: BCC lesion will be treated with long-pulse 1064 laser, with surface temperature monitored by infrared camera.
Study: NCT06295861

Intervention type: OTHER
Intervention: no different intervention between the two cohort.
Description: no different intervention between the two cohort.

Intervention type: OTHER
Intervention: no different intervention between the two cohort.
Description: no different intervention between the two cohort.
Study: NCT05663580

Intervention type: DRUG
Intervention: Cabotegravir 600mg/3mL, Rilpivirine 900mg/3mL
Description: Initial administration of two separate intramuscolar injection of cabotegravir 400mg/3mL and rilpivirine 600mg/3mL in opposite gluteal muscles, repeated one month later and then every two months.
Study: NCT04809285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app
Description: Guardian™ Connect system consists of Guardian™ Connect app, Guardian™ Connect transmitter, and Guardian Sensor (3), will be working with InPen™ Basal smart cap and smart insulin pens and InPen™ Diabetes Management app for multiple daily injections. The subject's insulin delivery, sleep, physical activity (as applicable), food intake data, and medication (as applicable) will be collected through applications with meal logging and medication requiring manual entry. In addition, subjects may also participate in optional self-administered insulin injection video capture and upload using a secure cloud-based site and/or monthly menstrual cycle logging using Apple Health and/or cardiac monitoring using BodyGuardian MINI.
Study: NCT05062161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene/extension intervention
Description: The 60-minute sleep hygiene/extension educational session include the following: This session will consist of questionnaires, handouts, videos, and a discussion. Topic examples include information on establishing a comfortable sleep environment, including strategies on how to extend sleep duration by a maximum of 1 hour over the duration of the 8-week trial for an average of 7.5 minutes per week, not to exceed 15 minutes per week. Participants will also receive educational brochures and a sleep diary.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control care
Description: The 60-minute educational session will address sleep physiology but not sleep hygiene. This session will consist of questionnaires, handouts, videos, and a discussion. Participants will receive an educational brochure.
Study: NCT04690959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neural mobilization
Description: Neural mobilization, or neurodynamics, is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neural mobilization
Description: Neural mobilization, or neurodynamics, is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: it is faked neural mobilization that mimic the neural mobilization treatment but believed not to stress the neural tissues in the upper extremity.
Study: NCT06251765

Intervention type: OTHER
Intervention: Clinical scores
Description: Clinical scores will be administered to patients

Intervention type: OTHER
Intervention: Range of Motion
Description: Evalutation of knee mobility
Study: NCT05891795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clascoterone 1% Top Cream
Description: Apply a thin layer to the affected area twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Apply a thin layer to the affected area twice daily.
Study: NCT06177626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: Aerobic training on stationary bike 5x a week for 30 minutes a day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training
Description: Training 5x a week for 30 minutes. Standard of care.
Study: NCT04691674

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopy
Description: Endoscopic removal of the pancreatic stent

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: Endoscopic removal of the pancreatic stent
Study: NCT05026424

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Balance oral nutritional drink - control
Description: Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance oral nutritional drink - test
Description: Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
Study: NCT05637515

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humira 40 MG in Prefilled Syringe
Description: Humira (40 mg every other week)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe
Description: • Subjects will receive Humira (initial dose of 80 mg \[2 × 40 mg\]; Day 1 administered subcutaneously (SC), followed by 40 mg SC given every other week starting 1 week after the initial dose (last dose at Week 10).~Hulio (40 mg every other week) at Week 12 and Week 14~* Humira (40 mg every other week) at Week 16 and Week 18, and~* Hulio (40 mg every other week) at Week 20, Week 22, Week 24 and Week 26.
Study: NCT06427382

Intervention type: DEVICE
Intervention: Perfusion index
Description: Perfusion index determination using non-invasive pulse oximetry

Intervention type: DEVICE
Intervention: Perfusion index
Description: Perfusion index determination using non-invasive pulse oximetry
Study: NCT04897854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfirinox
Description: In both arms the intervention will be FOLRINIOX or nab paclitaxel in combination with gemcitabine per investigator's choice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfirinox
Description: In both arms the intervention will be FOLRINIOX or nab paclitaxel in combination with gemcitabine per investigator's choice
Study: NCT06335784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Description: Imagery rescripting (IR) is a technique where the individual is instructed to imagine a negative memory or image as vividly as possible, and to change it in a direction that he/she desires. IR seems particularly efficient because it is based on the experienced emotions during perceptual information processing, thereby eliciting stronger emotional responses than verbal processing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR) and Targeted Memory Reactivation (TMR) during sleep
Description: Targeted Memory Reactivation (TMR) is a technique used to strengthen a memory trace during sleep. TMR is used to modify memory formation through the application of cues during sleep. In this TMR protocol, an olfactory cue is associated with the imagery rescripting (IR) during the day, and then administered during sleep. In that way, the replay of the associated memory and its corresponding neural representation in memory networks are artificially promoted, a procedure which usually strengthens memory consolidation. Previous studies have shown that TMR in sleep reduces emotional arousal, making it a promising technique for insomnia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: Sleep hygiene education includes modifications in the behavior (e.g., exercise, coffee, alcohol intake) and environment (e.g., light, noise, temperature conditions) that offer to the individual the foundation for healthy sleep. Sleep hygiene is an important component in treating ID, but insufficient and less effective than CBT-I when offered alone.
Study: NCT06330480

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention group
Description: Subjects will be invited for a home-based screening (phase 1) that includes home-based testing; urine collection for detection of elevated albuminuria, and a heart rhythm measurement for detection of atrial fibrillation. Both home-based tests will be performed with CE-marked medical devices used according to their intended use. A subset of the population will also receive a short questionnaire. Depending on the results of the home-based tests, subjects might be invited for further screening in a diagnostic screening facility (phase 2), that includes collection of physical data, blood, and urine for the assessment of parameters that are indicative of cardiovascular disease, chronic kidney disease, diabetes type 2 or their risk factors. Participants will also receive a questionnaire. Based on the results of the diagnostic screening, participants may be referred to their GP for appropriate treatment according to the prevailing guidelines (phase 3)